Wellbutrin Withdrawal: Why Bupropion Is Different From Every Other Antidepressant

Most advice about antidepressant withdrawal is written about SSRIs, and most of it does not transfer cleanly to bupropion. If you have read about brain zaps and are wondering why you are not getting them, or why your experience looks nothing like the accounts online, there is a straightforward reason.

Bupropion is not a serotonergic antidepressant — it acts primarily on dopamine and noradrenaline. Because the classic antidepressant discontinuation syndrome is largely a serotonergic phenomenon, bupropion generally produces milder discontinuation effects, and brain zaps are uncommon. Its real tapering difficulty is practical rather than pharmacological: XL tablets cannot be split, and the smallest is 150mg.

Why the usual symptoms mostly don't apply

The symptom cluster people associate with stopping antidepressants — brain zaps, dizziness, the flu-like heaviness, sensory disturbance — is tied to serotonin system readjustment. Bupropion does not meaningfully engage that system.

What people do report when reducing or stopping bupropion tends to be different in character: fatigue, low motivation, flattened mood, irritability, and sometimes a return of the symptoms bupropion was managing (including, for people who used it to stop smoking, cravings).

That last point matters and is easily missed. Because bupropion is prescribed for depression, seasonal affective disorder and smoking cessation, "what happens when I stop" depends heavily on why you started.

The real problem: you cannot split the tablet

Here is where bupropion tapering actually gets difficult, and it has nothing to do with neurochemistry.

Wellbutrin XL tablets are extended-release and cannot be split or crushed — doing so destroys the release mechanism and delivers the dose all at once, which matters more here than with most drugs because bupropion's seizure risk is related to dose and peak concentration. The smallest XL tablet is 150mg.

So a proportional taper hits a wall almost immediately. Reducing 10% from 300mg means a 270mg dose, and there is no way to make that from XL tablets.

The taper schedule builder flags this early for bupropion — not because the schedule is wrong, but because the formulation is the binding constraint from step one.

The options worth discussing

Because splitting is off the table, bupropion tapers usually work through form changes rather than fine dose adjustments:

• XL 300mg → XL 150mg is the standard first step, and it is a 50% reduction in one move. That is large by proportional-tapering standards, and worth acknowledging as such rather than treating as routine.
• Switching to SR (sustained-release) or IR (immediate-release) forms, which come in smaller strengths — this is the usual way to reach intermediate doses. It changes dosing frequency, so it is a prescriber decision.
• Compounded doses from a compounding pharmacy, at additional cost and usually without insurance coverage.

There is no US oral liquid formulation of bupropion.

Do not crush, split, or chew XL tablets

Worth stating separately because it is the one genuinely unsafe shortcut here. Bupropion carries a dose-related seizure risk, and extended-release formulations exist specifically to avoid high peak concentrations. Splitting an XL tablet defeats that.

If your schedule calls for a dose the available tablets cannot produce, the answer is a form change agreed with your prescriber — never a modified tablet.

What tends to be easier here

Some genuine good news, since most tapering content is relentlessly cautionary:

• Discontinuation symptoms are generally milder than with short-half-life serotonergic drugs like paroxetine or venlafaxine
• Bupropion's own half-life is around 21 hours with longer-lived active metabolites, which cushions the transition somewhat
• Brain zaps, the symptom people most dread, are not a typical feature

For most people the limiting factor on a bupropion taper is arranging the right tablet strengths, not enduring the reductions.

Watch for what it was treating

Because bupropion is activating rather than sedating, and is often prescribed for its effect on energy and motivation, its removal can be noticeable in ways that are easy to misread.

Worth tracking deliberately, and worth distinguishing with your prescriber:

• Fatigue and low motivation in the first weeks after a reduction may be adjustment
• A gradual return of depressive symptoms over weeks, resembling your original episode, may be relapse
• Returning nicotine cravings, if that was the indication, are a specific and predictable risk that deserves its own plan

A few weeks of the symptom tracker before and after each step makes this distinction far easier to see — and much easier to discuss at an appointment than trying to recall it from memory.

When to seek help promptly

• Any seizure — seek emergency care
• Thoughts of suicide or self-harm — stop and get help immediately (US: call or text 988; UK: 116 123)
• A depressive episode that is clearly returning and affecting function
• Symptoms that escalate rather than settle at a stable dose

Nothing here is medical advice. Never change your dose, split an extended-release tablet, or stop bupropion without your prescriber's involvement.